Market Challenges And Opportunities

Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market - Driver

Increase in the research and development activities by market players

Increasing research and development activities for Ornithine Transcarbamylase (OTC) deficiency treatment by market players is expected to drive the market growth over the forecast period. For instance, in April 2020, Arcturus Therapeutics, a clinical-stage messenger RNA medicine company, announced the acceptance of two clinical trials for its flagship asset ARCT-810, also known as LUNAR-OTC, a first-in-class mRNA therapeutic that is being developed to treat Ornithine Transcarbamylase (OTC) deficiency. The company’s Investigational New Drug (IND) application for Phase 1b study in patients with OTC deficiency was allowed to proceed by the U.S. Food and Drug Administration (FDA), and an additional Clinical Trial Application (CTA) for a Phase 1 study in healthy volunteers was approved by the New Zealand Medicines and Medical Devices Safety Authority (Medsafe).

Restraints & Challenges:

High cost of Ornithine Transcarbamylase (OTC) deficiency treatment drugs

Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market: Restraint

High cost of Ornithine Transcarbamylase (OTC) Deficiency Treatment

Drugs such as RAVICTI are a nitrogen-binding agent that are approved for the treatment of chronic management of urea cycle disorder (UCD) in adults and children. RAVICTI is developed by Horizon Therapeutics and it costs around US$ 793,632 for a year of treatment of patient suffering from urea cycle disorder. RAVICTI is one of the most expensive drugs available in the U.S. for the treatment of Ornithine Transcarbamylase (OTC) deficiency. Government should focus on reimbursement policies for Ornithine Transcarbamylase (OTC) deficiency to boost the growth of the market.